Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Anixa Biosciences, Inc. is a biotechnology company focused on developing novel immunotherapies and vaccines targeting unmet needs in oncology. Its core programs include a chimeric endocrine receptor CAR-T cell therapy for ovarian cancer and vaccines for triple-negative breast cancer and ovarian cancer, licensed from leading research institutions. Anixa’s business model centers on advancing clinical trials and partnering with pharmaceutical companies for manufacturing, marketing, and commercialization of its cancer therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.